Genmab: Number of Employees 2019-2022 | GMAB
Interactive chart of Genmab (GMAB) annual worldwide employee count from 2019 to 2022.
- Genmab total number of employees in 2021 was 1,212, a 55.19% increase from 2020.
- Genmab total number of employees in 2020 was 781, a 42.52% increase from 2019.
- Genmab total number of employees in 2019 was 548, a 30.79% increase from 2018.
- Genmab total number of employees in 2018 was 419, a INF% increase from .
| Genmab Annual Number of Employees | |
|---|---|
| 2021 | 1,212 |
| 2020 | 781 |
| 2019 | 548 |
| 2018 | 419 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $20.430B | $1.349B |
| Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $162.213B | 9.87 |
| Bio-Rad Laboratories (BIO.B) | United States | $15.121B | 32.79 |
| QIAGEN (QGEN) | Netherlands | $10.280B | 16.23 |
| Biohaven Pharmaceutical Holding (BHVN) | United States | $10.017B | 0.00 |
| Ginkgo Bioworks Holdings (DNA) | United States | $4.593B | 0.00 |
| Emergent Biosolutions (EBS) | United States | $1.775B | 7.60 |
| Arcus Biosciences (RCUS) | United States | $1.357B | 34.40 |
| Myovant Sciences (MYOV) | United Kingdom | $1.000B | 0.00 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.486B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.360B | 0.00 |
| Zymeworks (ZYME) | Canada | $0.346B | 0.00 |
| Ambrx Biopharma (AMAM) | United States | $0.149B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.116B | 23.80 |
| SQZ Biotechnologies (SQZ) | United States | $0.099B | 0.00 |
